Bolt Biotherapeutics, Inc. (BOLT)
| Market Cap | 8.17M -27.1% |
| Revenue (ttm) | 4.70M +12.8% |
| Net Income | -28.74M |
| EPS | -16.38 |
| Shares Out | 1.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,255 |
| Open | 4.140 |
| Previous Close | 3.980 |
| Day's Range | 3.850 - 4.440 |
| 52-Week Range | 3.100 - 7.200 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 29.00 (+583.96%) |
| Est. Earnings | Nov 11, 2026 |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembr... [Read more]
Financial Performance
In 2025, Bolt Biotherapeutics's revenue was $7.70 million, an increase of 0.07% compared to the previous year's $7.69 million. Losses were -$33.38 million, -47.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price target is $29.0, which is an increase of 583.96% from the latest price.
News
Bolt Biotherapeutics reports Q2 EPS ($4.57) vs. ($4.46) last year
Reports Q2 revenue $5,000, consensus $500,000. “In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and gastroesophageal ca...
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of Jun...
Bolt Biotherapeutics Earnings release: Q2 2026
Bolt Biotherapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Bolt Biotherapeutics Quarterly report: Q2 2026
Bolt Biotherapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May ...
Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $22 price target The firm cites the company’s “first-in-class” Claudin 18.2 immune-stimulating antibody conjuga...
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, tod...
Bolt Biotherapeutics Quarterly report: Q1 2026
Bolt Biotherapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Bolt Biotherapeutics Earnings release: Q1 2026
Bolt Biotherapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Bolt Biotherapeutics Proxy statement: Proxy filing
Bolt Biotherapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Bolt Biotherapeutics Proxy statement: Proxy filing
Bolt Biotherapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)
Reports Q4 revenue $2.5M, consensus $857,250. “BDC-4182 is the first of our next-generation Boltbody ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in…
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t...
Bolt Biotherapeutics Earnings release: Q4 2025
Bolt Biotherapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Bolt Biotherapeutics Annual report: Q4 2025
Bolt Biotherapeutics has published its Q4 2025 annual report on March 12, 2026.
Bolt Biotherapeutics to Participate in Upcoming March Conferences
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)
Reports Q3 revenue $2.17M, consensus $820,800. “In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody ISAC in our pipeline. We are actively enrolling patients wit...
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, ...
Bolt Biotherapeutics Earnings release: Q3 2025
Bolt Biotherapeutics released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.
Bolt Biotherapeutics Quarterly report: Q3 2025
Bolt Biotherapeutics has published its Q3 2025 quarterly earnings report on November 12, 2025.
Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $7 price target The company’s lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates sin...
Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study
Bolt Biotherapeutics (BOLT) announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in on...
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
Lake Street analyst Chad Messer raised the firm’s price target on Bolt Biotherapeutics (BOLT) to $75 from $4 and keeps a Buy rating on the shares after Bolt ended Q2…
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
Reports Q2 revenue $1.8M, consensus $819,750. “In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody(TM) ISAC in our pipeline,” said Willie Quinn, president and CE...